S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genprex, Inc. stock logo
GNPX
Genprex
$2.13
-4.1%
$3.67
$2.09
$45.20
$4.07M-0.6174,206 shs38,188 shs
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.01
$0.01
$0.01
$0.02
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$3.80
$3.51
$2.50
$4.42
$6.64M-0.123,200 shsN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
$2.06
$1.26
$4.26
$8.11M0.98162,968 shs2,579 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genprex, Inc. stock logo
GNPX
Genprex
0.00%-20.50%-34.62%-73.56%-94.42%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-53.85%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%-50.00%0.00%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+4.40%+2.98%+2.70%-3.06%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genprex, Inc. stock logo
GNPX
Genprex
4.2248 of 5 stars
3.55.00.04.70.60.81.3
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genprex, Inc. stock logo
GNPX
Genprex
3.00
Buy$10.00369.48% Upside
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest RELV, NEVPF, MSLP, REXN, and GNPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Genprex, Inc. stock logo
GNPX
Genprex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/25/2024
Genprex, Inc. stock logo
GNPX
Genprex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$10.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genprex, Inc. stock logo
GNPX
Genprex
N/AN/AN/AN/A$4.99 per shareN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A$0.04 per shareN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.19$0.09 per share44.53$6.36 per share0.60
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A$2.48 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genprex, Inc. stock logo
GNPX
Genprex
-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$8.45MN/A0.00N/AN/A-63.75%-57.93%N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genprex, Inc. stock logo
GNPX
Genprex
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genprex, Inc. stock logo
GNPX
Genprex
N/A
2.31
2.31
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
6.60
6.60
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/A
3.37
3.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Genprex, Inc. stock logo
GNPX
Genprex
14.05%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
7.49%

Insider Ownership

CompanyInsider Ownership
Genprex, Inc. stock logo
GNPX
Genprex
11.54%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
31.18%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
1.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Genprex, Inc. stock logo
GNPX
Genprex
311.91 million1.69 millionOptionable
MusclePharm Co. stock logo
MSLP
MusclePharm
2733.39 million13.12 millionNot Optionable
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8N/AN/ANot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
54.48 millionN/AOptionable

RELV, NEVPF, MSLP, REXN, and GNPX Headlines

SourceHeadline
Aurinia Pharmaceuticals Inc AUPHAurinia Pharmaceuticals Inc AUPH
morningstar.com - February 16 at 5:49 PM
MaxCyte Appoints Douglas Swirsky as Chief Financial OfficerMaxCyte Appoints Douglas Swirsky as Chief Financial Officer
benzinga.com - March 27 at 6:16 PM
Rexahn: Holes Galore in Serdaxin DataRexahn: Holes Galore in Serdaxin Data
thestreet.com - January 1 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Genprex logo

Genprex

NASDAQ:GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
MusclePharm logo

MusclePharm

OTCMKTS:MSLP
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Abliva AB (publ) logo

Abliva AB (publ)

OTCMKTS:NEVPF
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Rexahn Pharmaceuticals logo

Rexahn Pharmaceuticals

NASDAQ:REXN
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.